[Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]. (2016). Farmeconomia. Health Economics and Therapeutic Pathways, 17(2), 67-80. https://doi.org/10.7175/fe.v17i2.1251